Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UFM1 specific peptidase 1 (UFSP1) is an **active cysteine protease enzyme** involved in the post-translational modification pathway known as UFMylation, which is a ubiquitin-like system unique to metazoans and plants. UFSP1 is responsible for the **maturation of UFM1** (ubiquitin-fold modifier 1) by cleaving its C-terminal Ser-Cys dipeptide to expose the critical glycine residue required for subsequent conjugation to substrate proteins. Additionally, UFSP1, alongside UFSP2, catalyzes the removal of UFM1 from protein substrates, a process termed **de-UFMylation**. UFSP1 is widely expressed (though at a lower level than UFSP2 in humans), localizes primarily in the cytosol, and initiates translation from an upstream CUG codon, not the canonical AUG, to produce the active protease form[1][3]. The UFMylation pathway is **implicated in cellular processes such as erythropoiesis, endoplasmic reticulum (ER) homeostasis, and response to stress**, and deficiencies or mutations in UFMylation components—including *UFSP1*—are associated with embryonic lethality in mice and a range of human diseases, including neurological and skeletal disorders, and cancer[1][3]. UFSP1 is not currently known to be directly targeted by approved drugs, nor is it a routine clinical biomarker. No common drugs or clinically used UFSP1-targeting inhibitors or activators are reported, nor are notable safety or toxicity issues specifically described for UFSP1 modulation as of the cited research[1][3].
Cleavage of the C-terminal Ser-Cys dipeptide from the UFM1 precursor to generate mature UFM1[1][3], Removal of UFM1 from conjugated protein substrates (de-UFMylation)[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UFM1 specific peptidase 1 (UFSP1).